EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features
about
Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancerExpression of STAT5, COX-2 and PIAS3 in correlation with NSCLC histhopathological features.Expression of COX-2, CD44v6 and CD147 and relationship with invasion and lymph node metastasis in hypopharyngeal squamous cell carcinoma.TGF-β1 downregulates COX-2 expression leading to decrease of PGE2 production in human lung cancer A549 cells, which is involved in fibrotic response to TGF-β1.Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with non-small cell lung cancerNon-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategiesIdentification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.Stimulating immune responses to fight cancer: Basic biology and mechanisms.Dysregulation of angiogenesis-specific signalling in adult testis results in xenograft degeneration.[Effects of EGFR gene polymorphisms on efficacy and prognosis in advanced non-small cell lung cancer treated with EGFR-TKIs].Protein predictive signatures for lymph node metastasis of gastric cancer.Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma.Correction: EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features.Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution.Cyclooxygenase inhibitors combined with deuterium-enriched water augment cytotoxicity in A549 lung cancer cell line via activation of apoptosis and MAPK pathways.
P2860
Q28816916-C9A29EFE-701F-4762-BA7D-D4B464B50D19Q34066293-4D20078A-6004-4751-8373-DCBBDB5B2A88Q34982652-F8676F0E-D18F-48B2-9E8D-789650C3A6CAQ35009383-05D6D041-69E9-4D7C-8AF0-4ABF3FDE210DQ36285667-C878BEFD-BEEA-4848-9920-2B8DA7020D0CQ36850900-E5D5E103-2FF5-4650-BEF3-7FC090823E75Q37662128-E83872CE-CE73-446D-B78A-DBF90924F77DQ38578898-D38D1CA2-B118-4DC3-A4CF-4DB0B718A85BQ42230465-5A00F4F3-186E-4819-A1DC-03902D3361C7Q44919323-CB87BBA7-D014-4413-8CE2-BAA30D4F9DEFQ46429361-87DB04E4-A04D-44B7-AAFD-A64BE28A15FAQ48249218-CB4E104D-CD0E-4F3C-9D9D-9F177E13D79CQ50328930-9E6378E0-6DBF-4D6B-93F5-FD4EF3FF3A63Q54388141-740508D2-B8F2-4145-BC53-30E181DC8AEFQ55172105-762A1CC9-888C-41A7-AD19-C8CE51970DFC
P2860
EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
EGFR and COX-2 protein express ...... elation with clinical features
@ast
EGFR and COX-2 protein express ...... elation with clinical features
@en
EGFR and COX-2 protein express ...... elation with clinical features
@nl
type
label
EGFR and COX-2 protein express ...... elation with clinical features
@ast
EGFR and COX-2 protein express ...... elation with clinical features
@en
EGFR and COX-2 protein express ...... elation with clinical features
@nl
prefLabel
EGFR and COX-2 protein express ...... elation with clinical features
@ast
EGFR and COX-2 protein express ...... elation with clinical features
@en
EGFR and COX-2 protein express ...... elation with clinical features
@nl
P2093
P2860
P356
P1476
EGFR and COX-2 protein express ...... elation with clinical features
@en
P2093
Dianying Liao
Huijiao Chen
Yongmei Liu
P2860
P2888
P356
10.1186/1756-9966-30-27
P577
2011-03-07T00:00:00Z
P5875
P6179
1030218866